Advertisement

Medical Management of Benign Prostatic Hyperplasia

  • Victor C. ShowalterEmail author
  • Mathew C. Raynor
Chapter

Abstract

The goal of medical management for benign prostatic hyperplasia (BPH) is to improve lower urinary tract symptoms (LUTS) of affected patients. Therapy is generally focused on mitigating the dynamic or static components of BPH pathophysiology. Alpha-adrenergic receptor blockers (alpha-blockers) are the most common first-line medication for BPH and function by inhibiting dynamic prostatic smooth muscle contraction to prevent bladder outlet obstruction. The medications in this class are equally effective and well tolerated, but medication side effects of hypotension, dizziness, and retrograde ejaculation determine specific medication selection for treatment. Androgen manipulation via 5 alpha-reductase inhibitors alleviates static components of LUTS by decreasing prostate size. This medication class can potentiate sexual side effects but has been shown to be extremely effective in conjunction with alpha-blockers. Phosphodiesterase inhibitors have demonstrated efficacy in treating men with BPH and coexisting erectile dysfunction, but their mechanism of improving LUTS is unclear. Anticholinergic and beta-3-agonist medications are indicated for patients with overactive bladder symptoms in the setting of BPH due to their ability to reduce detrusor spasms and increase bladder relaxation.

Keywords

Benign prostatic hyperplasia (BPH) Medical management Alpha antagonist (α-agonist) 5-Alpha-reductase inhibitor (5α-reductase inhibitor) Phosphodiesterase-5 inhibitors (PDE5 inhibitor) Anticholinergic Mirabegron 

References

  1. 1.
    Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attribbuted to benign prostatic hyperplasia: AUA guideline. Linthicum Heights: American Urology Association; 2018.Google Scholar
  2. 2.
    McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in America. Urol Clin North Am. 2009;36(1):11–27.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975;47(2):193–202.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent areadensity of prostate smooth muscle. Prostate. 1992;21(4):297–307.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of intravesical obstruction. Prostate. 1989;15(2):105–14.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    James S, Chapple C, Phillips M, Greengrass P, Davey M, Turner-Warwick R, et al. Autoradiographic analysis of the alpha-adrenoreceptos and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol. 1989;142(2 Pt 1):438–44.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Forray C, Bard J, Wetzel J. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45:703–8.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151(3):763–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50(7):551–4.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Ferrie B, Paterson P. Phenoxybenzamine in prostatic hypertrophy a double blind study. Br J Urol. 1987;59(1):63–5.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Ruutu M, Hansson E, Juusela H, Permi J, Rusk J, Sotarauta M, et al. Efficacy and side effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol. 1991;25(1):15–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Jardin A, Bensadoun H, Delauche-Cavallier M, Attatli P. Alfuzosin for benign prostatic hypertrophy. Lancet. 1991;338(8772):947.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Alabaster V, Davey M. The alpha 1-adrenoceptor antagonist profile of doxazosin; preclinical pharmacology. Br J Clin Pharmacol. 1986;21(Suppl 1):9S–17S.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Elliot H, Meredith P, Reid J. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987;59(14):78G–81G.CrossRefGoogle Scholar
  16. 16.
    Sonders R. Pharmacokinetics of terazosin. Am J Med. 1986;80(5B):20–4.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Guay D. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004;2(1):14–23.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia United States 93-01 Study Group. J Urol. 1998;160:1701–6.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Ding H, Du W, Hou Z, Wang H, Wang Z. Silodosin is effective for treatment of LUTS in men with BPH: a systemic review. Asian J Androl. 2013;15(1):121–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld K, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol. 2010;70(1):88–101.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Lepor H, Hill L. Sildosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010;30(12):1303–12.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia HYCAT Investigator Group. Urology. 1996;47(2):159–68.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Terazosin Abbot Laboratories. Hytrin (terazosin hydrochloride tablet) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf. Revised 07/2009. Accessed July 1, 2019.
  24. 24.
    Cr C, Carter P, Christmas TJ, Kriby RS, Bryan J, Milroy EJ, et al. A three month double blind study of doxazosinas treatment for benign prostatic obstruction. Br J Urol. 1994;74(1):50–6.CrossRefGoogle Scholar
  25. 25.
    Fawzy A, Braun K, Lewis G, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154(1):105–9.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose response multicenter study. J Urol. 1995;154(1):110–5.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bouedillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol. 1994;74(5):579–84.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Buzelin J, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol. 1997;31(2):190–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Van Kerrebroeck P, Jardin A, Laval K, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37(3):306–13.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Roerborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blinded, placebo-controlled studies. BJU Int. 2003;92(3):257–61.CrossRefGoogle Scholar
  31. 31.
    Yamada S, Tanaka C, Kimua R, Kawabe K. Alpha 1-adrenoreceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci. 1994;54(24):1845–54.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Wilt T, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction; a systematic review of efficacy and adverse effects. J Urol. 2002;167(1):177–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Uses of an α1-Blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol. 1990;144(4):908–11.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective α1c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76(3):325–36.PubMedCrossRefGoogle Scholar
  35. 35.
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51(6):892–900.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective α1A-adrenoreceptor antagonist, in patients with benign prostatic obstruction. BJU Int. 1997;80(4):587–96.CrossRefGoogle Scholar
  37. 37.
    Chapple C, Wyndaele J, Nording J, Boeminghaus F, Ypma A, Abrams P. Tamsulosin, the first prostate-selective 1A-adrenoreceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155–67.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Sildosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013;15(1):121–8.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Kawabe K, Yoshida M, Homma Y. Silodosin. A new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active controlled clinical trial performed in Europe. Eur Urol. 2012;(5):38–42, 44–5.Google Scholar
  42. 42.
    Lepor H. Long term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 1995;45(3):406–13.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Van Dijk M, de la Rosette J, Michel M. Effects of alpha(1)-adrenoreceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.PubMedCrossRefGoogle Scholar
  44. 44.
    Buzelin J, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol. 1997;80(4):597–695.PubMedCrossRefGoogle Scholar
  45. 45.
    Nordling J. Efficacy and safety of two doses (10mg and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005;95(7):1006–12.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Shakir S, Pearce G, Mann RD. Finesteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription event monitoring data. BJU Int. 2001;87:789–96.PubMedCrossRefGoogle Scholar
  47. 47.
    Brookes S, Donovan J, Peters T, Abrams P, Neal D. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. BMJ. 2002;324(7345):1059–61.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Hellstrom WJ, Smith W, Sikka SC. Effects of alpha blockers on ejaculatory function in normal subjects. J Urol. 2006;173(4 Pt 1):1529–33.CrossRefGoogle Scholar
  49. 49.
    Chang D, Campbell J. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–73.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Wilson J. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980;68(5):745–56.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Siiteri P, Wilson J. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970;49(9):1737–45.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Moore R, Gazyk J, Quebbeman J, Wilson J. Concentration of dihydrotestosterone and 3a-androstanediol in naturally occurring and androgen induced prostatic hyperplasia in the dog. J Clin Invest. 1979;64(4):1003–10.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    McConnell J. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate. 1990;17(S3):49–59.CrossRefGoogle Scholar
  54. 54.
    Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5a-reductase in humans. Prostate. 1989;14(1):45–53.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol. 1998;11:393–422.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnel JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety study Group. N Engl J Med. 1998;228(9):557–63.CrossRefGoogle Scholar
  58. 58.
    Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Mocellini IA, Gardiner R, Marshall V, Johnson W, Bartsch G, Schmidbauer CP, et al. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22(4):291–9.CrossRefGoogle Scholar
  62. 62.
    Marberger M. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51(5):677–86.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43(3):284–92; discussion 292-4.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrhorn C. Efficacy and safety of long-term treatment with dual 5-alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–94; discussion 495PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Guess H, Heyse J, Gormley G. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22(1):31–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Wein A, Kavoussi L, Partin A, Peters C. Chapter 104, evaluation and nonsurgical management of benign prostatic hyperplasia. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016.Google Scholar
  67. 67.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of Dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Burnett A. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “aging male” symptoms? Results of the “Cologne male survey”. Eur Urol. 2003;44(5):588–94.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Blanker MH, Bohnen AM, Groeneveld FP, Bersen RM, Prins A, Thomas S, et al. Correlates for erectile dysfunction in older men: a community-based study. J Am Geriatr Soc. 2001;49(4):436–42.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Moreira ED, Lbo CF, Diament A, Nicolsi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61(2):431–6.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfuntion in four centers: the UrEpik study. BJU Int. 2003;92(7):719–25.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Brookes S, Link C, Donovan J, McKinlay J. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J Urol. 2008;179(1):250–5.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836–9.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Roehrboen C, McVary K, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia; a dose finding study. J Urol. 2008;180(4):1228–34.CrossRefGoogle Scholar
  78. 78.
    Porst H, Oekle M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and safety of tadalifil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analysis of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667–73.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2012;61(5):994–1003.Google Scholar
  80. 80.
    McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Slidenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trail. J Urol. 2007;177(3):1071–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in helathy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010;106:674–80.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Thomas A, Abrams P. Lower urinary tract symptoms benign prostatic obstruction, and the overactive bladder. BJU Int. 2000;85(3):57–68.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn. 1985;4(4):317–28.CrossRefGoogle Scholar
  85. 85.
    Speakerman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosing JA. Bladder outflow obstruction—a cause of denervation super sensitivity. J Urol. 1987;136(6):1461–6.CrossRefGoogle Scholar
  86. 86.
    Greenland J, Brading A. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165:245.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Elbadawi A, Yalla S, Resnick N. Structural basis for geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150(5 Pt 2):1668–80.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Abramov Y, Sand P. Oxybutynon for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother. 2004;5(11):2351–9.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Elterman D, Kaplan S, Barkin J. Tolterodine for treatment of urge incontinence. Expert Opin Pharmacother. 2013;14(14):1987–91.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Blake-James B, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systemic review and meta-analysis. BJU Int. 2007;99(1):85–96.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Martin-Merino E, Garcia Rodriguez L, Masso Gonzales E, Roehrborn C. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009;182(4):1442–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in management of overactive bladder. Ther Adv Urol. 2012;288:1367–73.Google Scholar
  93. 93.
    Suarez O, Osborn D, Kaufman M, Reynolds WS, Dmochowski R. Curr Urol Rep. 2013;14(6):580–4.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al. Absorption, metabolism and excretion of (14)mirabegron (YM178), a potent and selective β(3)-adrenoreceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Chapple C, Cardozo L, Victor W, Nitti V, Siddiqui E, Michel M. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, et al. Proarrythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double blind placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milson I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double blind, parallel-group, placebo-controlled, multicenter study to assess the efficacy and safety of β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gromley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med. 1996;335(8):533–9.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Debruyne FMJ, Jardin A, Colloi D, Resel L, Wities WPJ, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, Finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 1998;34(3):169–75.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    McConnell JD, Roehrborn C, Bautista O, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long term effect of doxazosin, finasteride and combination theraopy on clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Kaplan SA, Roehrborn CG, Rovner ES, Carisson M, Bavendam T, Gaun Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Kaplan SA, Walmsely K, Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–6.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int. 2004;94:817–20.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Kaplan S, Roehrborn C, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109(12):1831–40.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin pluc tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398–407.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of North Carolina School of MedicineChapel HillUSA
  2. 2.Department of UrologyUniversity of North Carolina HospitalsChapel HillUSA

Personalised recommendations